Androgen receptors beyond prostate cancer: an old marker as a new target.

Permalink
https://escholarship.org/uc/item/7zn6t06k

Journal
Oncotarget, 6(2)

ISSN
1949-2553

Authors
Munoz, Javier
Wheler, Jennifer J
Kurzrock, Razelle

Publication Date
2015

DOI
10.18632/oncotarget.2831

Peer reviewed
Androgen receptors beyond prostate cancer: an old marker as a new target

Javier Munoz1,*, Jennifer J. Wheler2,*, and Razelle Kurzrock3

1 Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona
2 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas
3 Center for Personalized Cancer Therapy, Division and Hematology and Oncology, Moores Cancer Center, The University of California San Diego, La Jolla, California

* These authors share first authorship

Correspondence to: Jennifer J. Wheler, email: jjwheler@mdanderson.org

Keywords: androgen receptor, therapy, molecular abnormalities, phase I clinical trials

Received: October 16, 2014  Accepted: November 14, 2014  Published: November 15, 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Androgen receptors (ARs) play a critical role in the development of prostate cancer. Targeting ARs results in important salutary effects in this malignancy. Despite mounting evidence that ARs also participate in the pathogenesis and/or progression of diverse tumors, exploring the impact of hormonal manipulation of these receptors has not been widely pursued beyond prostate cancer. This review describes patterns of AR expression in a spectrum of cancers, and the potential to exploit this knowledge in the clinical therapeutic setting.

INTRODUCTION

Treatments targeting androgen receptors (ARs) have demonstrated efficacy in patients with prostate cancer. Despite a wealth of reports indicating that ARs may contribute to the growth and/or progression of numerous other malignancies, their precise role in cancers beyond those of the prostate is poorly understood. The aim of this review is to illuminate current data in the literature regarding the expression and functional impact of ARs in a range of solid tumors (Table 1), and to discuss the therapeutic implications of AR positivity.

Background

Androgen synthesis and androgen receptors: The goal of androgen deprivation or suppression therapy is to reduce the levels of male hormones (androgens) [1]. The major androgens capable of stimulating the androgen receptors include testosterone and dihydrotestosterone (DHT) [2]. In normal men, androgens are synthesized in the testes (interstitial Leydig cells) and adrenals. Testosterone is the principal circulating androgen in adult men, with >95% being of testicular origin [3] (under the regulatory control of the hypothalamic / pituitary axis), while the remainder originates from peripheral conversion of weaker precursors of adrenal origin: dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione [4]. Adrenal androgens are under adrenocorticotropic hormone (ACTH) control [5]. The adrenals and peripheral conversion/synthesis of androgens do not make a major contribution to androgen effects in the normal man, but may become a significant residual source of AR stimulation in men undergoing androgen deprivation/suppression therapy. Skin, fat, liver, and urogenital systems are important peripheral sites of androgen production [6, 7].

Prostate cancer as a model for androgen deprivation therapy: Androgens stimulate AR+ cells to proliferate. Since the vast majority of prostate cancers are AR+, androgen deprivation (suppression) treatment was a rational approach for this malignancy, and has become a cornerstone of treatment for advanced prostate cancer (Table 2) [8]. Androgen deprivation can shrink or stabilize prostate tumors, but is not generally curative. There are protean ways to suppress androgen levels. These include:

- Surgical removal of the testes (castration or orchiectomy).
- Luteinizing hormone-releasing hormone (LHRH) analogs (reversible chemical castration). These drugs halt testosterone production by the testicles.
Examples of these agents include leuprolide, goserelin, triptorelin, and histrelin [9]. When LHRH analogs are initiated, testosterone levels rise before falling, a phenomenon known as a “clinical flare” [10]. The flare can cause bone pain or spinal cord compression if tumors are present in these areas, as the tumors may have a short-lived growth spurt. The flare can be prevented by giving anti-androgens for a few weeks when LHRN analogs are started.

- Luteinizing hormone-releasing hormone (LHRH) antagonists. LHRH antagonists such as degarelix work like LHRH agonists, but they reduce testosterone levels more rapidly and do not induce a tumor flare like the LHRH agonists do [11].
  - Anti-androgens. Anti-androgens impede the body’s ability to use androgens, usually by blocking the androgen receptor. Even after orchiectomy or during treatment with LHRH analogs, the adrenal glands still synthesize small amounts of androgens. Drugs of this type include flutamide, bicalutamide, and nilutamide [12].
  - Other androgen-suppressing drugs. Estrogens were once the main alternative to orchiectomy for men with advanced prostate cancer. Because of their toxic effects [13] (including blood clots and breast enlargement), oral estrogens have been largely replaced by LHRH analogs and anti-androgens [14]. It has been suggested that

Table 1: Androgen receptor (AR) expression across malignancies.

| Malignancy             | Subtype                  | AR positivity % (positive/tested)* | Supplementary References |
|------------------------|--------------------------|------------------------------------|--------------------------|
| Adrenocortical carcinoma | Not specified            | 38% (6/16)                         | [S49]                    |
| Astrocytoma            | Grade I/II               | 28% (5/18)                         | [S89]                    |
| Astrocytoma            | Anaplastic               | 75% (3/4)                          | [S89]                    |
| Basal cell carcinoma   | Not specified            | 65% (20/31) - 78% (25/32)          | [S34, S35]               |
| Bladder cancer         | Urothelial carcinoma     | 12.9% (61/472) - 51% (7/139)       | [S55, S55]               |
| Breast cancer          | Her-2 adenocarcinoma     | 85.6% (89/104)                     | [S110]                   |
| Breast cancer          | BRCA1                    | 32% (43/135)                       | [S112]                   |
| Breast cancer          | BRCA2                    | 13% (18/135)                       | [S112]                   |
| Breast cancer          | BRCA negative            | 76% (56/74)                        | [S112]                   |
| Cervical invasive carcinoma | Squamous               | 23% (3/13)                        | [S91]                    |
| Colon adenocarcinoma   | Not specified            | 38% (5/13)                         | [S80]                    |
| Desmoid tumors         | Not specified            | 52.9% (14/27)                      | [S85]                    |
| Esophageal carcinoma   | Not specified            | 25% (1/4) - 33% (7/21)             | [S69]                    |
| Gastric carcinoma      | Not specified            | 12.5% (2/16) - 39% (46/117)        | [S65, S67]               |
| Glioblastoma multiformis | Not specified          | 40% (4/10)                       | [S89]                    |
| Head and neck carcinoma | Laryngeal squamous      | 0% - 10% (1/10)                    | [S26, S27]               |
| Juvenile nasopharyngeal fibroma | Not specified     | 38.4% (5/13) - 75% (18/24)         | [S22, S23]               |
| Melanoma               | Not specified            | 4% - 40%                           | [S30]                    |
| Meningioma             | Not specified            | 42% (8/19)                         | [S90]                    |
| Non-small cell lung cancer | Not specified         | 31% (20/64) - 70.5% (12/17)        | [S62, S63]               |
| Ovarian cancer         | Epithelial              | 18% (28/154) - 27% (7/26)          | [S101, S105]             |
| Ovarian cancer         | Steroid cell tumors     | 64% (9/14)                         | [S100]                   |
| Pancreatic adenocarcinoma | Not specified          | 0% (0/12)                          | [S72]                    |
| Peritoneal mesothelioma | Not specified           | 65%                                | [S35]                    |
| Prostate cancer        | Not specified            | 95%                                | [S58]                    |
| Testicular germ cell   | Seminoma                | 45%                                | [S44]                    |
| Thymic carcinoma       | Not specified            | 0% (0/12)                          | [S19]                    |
| Thymoma                | B3 thymoma              | 58.8% (10/17)                      | [S19]                    |
| Thyroid carcinoma      | Papillary               | 79% - 80% (4/5)                    | [S11, S56]               |
| Thyroid carcinoma      | Follicular              | 14% (4/28)                         | [S11]                    |
| Thyroid carcinoma      | Medullary               | 2% - 1.4% (4/28)                   | [S11, S12]               |
| Thyroid carcinoma      | Anaplastic              | 1%                                 | [S11]                    |
| Rectal adenocarcinoma  | Not specified            | 39% (9/23)                         | [S80]                    |
| Renal cancer           | Not specified            | 14.8% (27/182) - 42% (5/12)        | [S45, S46]               |
| Salivary gland         | Pleomorphic adenoma     | 4.8% (2/41) - 100% (14/14)         | [S2]                     |
| Salivary gland         | Salivary duct carcinoma | 92% (11/12) - 100% (6/6)          | [S1, S2, S4-S6]          |
| Salivary gland         | Mucoepidermoid carcinoma | 6.6% (2/30) - 20% (2/10)         | [S2]                     |
| Salivary gland         | Adenoid cystic carcinoma | 0% (0/8) - 20% (2/10)         | [S2]                     |
| Sarcoma                | Kaposi                   | 0% (0/22)                          | [S42]                    |
| Sarcoma                | Osteosarcoma            | 28.5% (8/28) - 50.8% (33/65)       | [S36, S37]               |
| Uterine sarcoma        | Leiomyosarcoma          | 0% (0/28) - 40% (10/25)            | [S95, S97]               |
| Uterine sarcoma        | Endometrial stromal     | 45% (9/20)                         | [S96]                    |
| Uterine carcinoma      | Endometrial carcinoma   | 16% (4/25) - 88.6% (39/44)         | [S93, S94]               |

* Numerators and denominators in the third column were given when they were clearly defined in the references.
Ketoconazole, first used for treating fungal infections, blocks production of androgens. It offers a quick way to lower testosterone levels, and it is used in countries where abiraterone has yet to be approved [16]. Abiraterone inhibits 17 α-hydroxylase/C17,20 lyase (CYP17A1), an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes key reactions in the testosterone synthesis pathway; inhibition of CYP17 [17] activity by abiraterone thus interferes with the processes in the testes and the adrenals leading to testosterone production.

Androgen deprivation has important side effects [18, 19], especially in men: reduced or absent libido, impotence; hot flashes, gynecomastia, osteoporosis and fractures, attenuated mental acuity, loss of muscle mass, depression, and fatigue.

I. HEAD AND NECK CANCERS

Salivary gland tumors: Remarkable similarities between breast cancer and salivary gland tumors have been documented [S1-S3]. Not only is HER2/neu expression frequent in these tumors, but estrogen receptors (ER) and progesterone receptors (PR) are expressed in 33.3% (13/69) and 86.9% (60/69), respectively, in the pleomorphic adenoma subtype [S3]. AR positivity has also been documented in salivary duct carcinomas [S1, S4-S6]. Nasser et al. [S2] reported a series of 78 formalin-fixed, paraffin-embedded salivary gland tumors with strong positivity for AR in 100% (14/14) of carcinoma ex-pleomorphic adenomas and 100% (6/6) of salivary duct carcinomas. Fan et al. [S5] reported AR positivity rates as high as 92% (11/12) in salivary duct carcinomas. AR reactivity was also seen in 20% (2/10) of acinic cell carcinomas, 20% (2/10) of mucoepidermoid carcinomas, and 20% (2/10) of adenoid cystic carcinomas [S2]. In the same study all 26 benign salivary gland tumors were negative for expression of AR [S2].

In regard to treatment, Locati et al. [S7] reported a complete remission with androgen deprivation therapy in a patient with recurrent AR-expressing adenocarcinoma of the parotid gland. Kuroda et al. [S8] reported a partial response after one course of anti-androgen therapy and palliative chemotherapy with paclitaxel in a patient with advanced salivary duct carcinoma.

Table 2: Examples of Anti-Androgens Approved by the Food and Drug Administration (FDA) agents to treat prostate cancer

| Drug name       | Mechanism of action                  | Indication Examples                                                                 |
|-----------------|--------------------------------------|-------------------------------------------------------------------------------------|
| Leuprolide acetate | GnRH” agonists                  | Palliative treatment of advanced prostatic cancer.                                    |
| Goserelin acetate   | GnRH agonists                     | Palliative treatment of advanced prostatic cancer.                                    |
| Triptorelin pamoate | GnRH agonists                    | Palliative treatment of advanced prostatic cancer.                                    |
| Histrelin acetate   | GnRH agonists                     | Palliative treatment of advanced prostatic cancer.                                    |
| Degarelix acetate   | GnRH antagonists                   | Palliative treatment of advanced prostatic cancer.                                    |
| Bicalutamide      | Binds to androgen receptor         | Metastatic prostate cancer                                                           |
| Flutamide         | Competes for AR the and dihydrotestosterone for the androgen receptor | """"                                                                                           |
| Nilutamide        | Blocks AR                          | Advanced prostate cancer                                                             |
| Abiraterone acetate | CYP17A1 inhibitor                  | Metastatic castration-resistant prostate cancer who have received prior docetaxel.     |
| Enzalutamide      | Androgen receptor inhibitor        | Metastatic castration-resistant prostate cancer who have received prior docetaxel.     |
| Radium Ra 223 dichloride | Alpha-particle emitting   | Symptomatic bone metastases and no known visceral metastatic disease.                  |

* Data from www.fda.gov (Accessed August 11, 2014).
** AR = androgen receptor; GnRH: gonadotropin releasing hormone.
is papillary (~79%), followed by follicular (~14%), medullary (~2%), anaplastic (~1%) and other histological subtypes (~4%) [S11]. There are significant rates of recurrence with current therapeutic approaches such as surgery or radioactive iodine therapy [S9]. Because both benign and malignant thyroid lesions are more common in women than in men, it has been suggested that sex hormones play a role. Certainly somatic mutations in BRCA, RAS and RET, all described in thyroid cancer, are not known to account for the gender disparity [S10].

Bléchet et al. [S12] showed AR positivity by immunohistochemistry (IHC) in 14% (4/28) of medullary thyroid carcinomas. Testosterone increased dose-dependent proliferation of AR+ human papillary thyroid cancer cell lines; whereas flutamide, inhibited testosterone-induced cell proliferation [S13]. Wiseman et al. [S14] examined differentiated thyroid cancer and found AR+ in 50.5% (50/99) compared to 2% (2/100) of benign lesions. Prinz et al. [S15] showed AR+ in 17 of 31 cases of thyroid cancer, including 80% (4/5) of papillary carcinomas and 80% (4/5) of follicular adenomas. Despite high AR expression in thyroid cancer, there are only anecdotal reports of therapeutic hormonal manipulation [S16].

Thymoma and thymic carcinoma: Ishibashi et al. [S17] examined patients with thymoma and found AR+ nuclear immunoreactivity by IHC in 15% of patients (20/132). Mimae et al. [S18] studied thymic epithelial tumors (103 thymomas and 37 thymic carcinomas) and found that 23.6% expressed AR. The World Health Organization (WHO) classified epithelial thymic tumors into six types including A, AB, B1, B2, B3, and thymic carcinoma. Because the histological differential diagnosis between type B3 thymoma and thymic carcinoma can be challenging, Khoury et al. [S19] proposed that AR might be useful for pinpointing the diagnosis, particularly because cytoplasmic AR was found in 58.8% (10/17) of type B3 thymomas versus 0% (0/12) of thymic carcinomas [S19]. Preclinical data suggest that blocking AR with 5-alpha-dihydrotestosterone can initiate apoptosis in thymoma cells [S20].

Juvenile nasopharyngeal angiofibroma: Several publications have documented that these benign hormone-dependent tumors, particularly the ones prone to affecting adolescent males, express AR [S21, S22]. IHC results showed AR+ in 75% (18/24) of nasopharyngeal angiofibroma cases [S23]. Montag et al. [S24] showed that AR is expressed in 38.4% (5/13) of patients. These results translated to the clinic where 4 of 5 patients with juvenile nasopharyngeal angiofibroma demonstrated an average shrinkage of 44% following flutamide [S25].

Head and neck carcinomas: Bianchini et al. [S26] studied tissue from 15 patients with laryngeal carcinoma but found no expression of AR (0%) [S26]. Virolainen et al. [S27] found 10% (1/10) AR positivity in cell lines derived from laryngeal squamous cell carcinoma and 0% (0/9) AR positivity in non-laryngeal head and neck squamous tumors. Mattox et al. [S28] evaluated flutamide in patients with laryngeal carcinoma and, surprisingly, short-lived partial responses were seen in 3 of 9 patients. AR levels did not correlate with response [S28].

II. CUTANEOUS MALIGNANCIES

Melanoma: AR reactivity was present in 40% of melanomas; however, it was also observed in 41% of normal skin [S29]. In contrast, a different report (N=142 patients with malignant melanoma) discerned AR positivity in only 4% of cases [S30]. Morvillo et al. [S31] showed AR+ in human melanoma cell lines, with tumor growth after exposure to dihydrotestosterone versus significant inhibition of proliferation after tamoxifen or flutamide [S32]. Ketoconazole, an androgen synthesis inhibitor, was shown to abrogate the metastatic potential of melanoma cell lines in mice [S33].

Basal cell carcinoma: Katona et al. [S34] and Izikson et al. [S35] reported AR expression in 65% (20/31) and 78% (25/32), respectively, of basal cell carcinoma cases; they suggested that the expression was high enough to help distinguish basal cell carcinoma from other skin conditions with low or negative AR expression, such as benign trichoblastic tumors and desmoplastic trichoepithelioma.

III. SARCOMA

Limited studies of AR in sarcomas have been performed.

Osteosarcoma: AR+ has been demonstrated in 28.5% (8/28) to 50.8% (33/65) of osteosarcomas [S36, S37]. Proliferation of osteosarcoma cell lines in vitro was stimulated by estradiol, progesterone, and 5 alpha-dihydrotestosterone; whereas growth was abrogated by AR antagonists as fulvestrant, mifepristone, and hydroxiflutamide. Interestingly, higher levels of AR correlated with a higher degree of differentiation. In preclinical models, the adrenal androgen synthesis inhibitor ketoconazole prompted apoptosis in human osteosarcoma cells [S38].

Other malignant sarcomas: We were unable to find AR expression data regarding gastrointestinal stromal tumors in the literature [S39, S40]. In 1980, Walker et al. [S41] reported steroid receptors in malignant skeletal malignancies, including four cases of osteosarcoma, two chondrosarcomas, one malignant giant cell tumor, and one Ewing’s sarcoma. Cytoplasmic AR and PR were expressed in three of seven cases (43%) [S41]. Ziegler et al. [S42] found 0% (0/22) AR expression in tissue from 22 patients with Kaposi’s sarcoma.

IV. GENITOURINARY MALIGNANCIES

Testicular germ cell tumors: There was no AR staining in embryonal carcinoma, mature teratoma, seminoma, or mixed germ cell tumors, although trace AR expression was found in 3 out of 5 cases of endodermal...
sinus tumors [S43]. In a small study of seminomas, AR expression was detected in 45% of cases (N = 18) [S44].

Renal cell carcinoma: AR expression has been demonstrated in 14.2% (3/21), 14.8% (27/182) and 42% (5/12) of renal cell carcinomas [S45-S47]. AR positivity was associated with a significantly better progression-free survival (PFS) compared to AR negativity in renal cancer [S45]. Brown et al. [S46] demonstrated AR immunoreactivity in 5 of 12 patients with primary and in 1 of 5 of patients with metastatic clear cell renal cell carcinoma. Based on a small number of patients, Nakano et al. [S15] hypothesized that hormonal manipulation exerted no antineoplastic effect vis-a-vis tumor shrinkage, but did prolong survival in the subgroup with hormonal receptor positivity. A phase II trial of flutamide, a nonsteroidal antiandrogen, in 25 patients with advanced renal cell cancer, demonstrated one partial response for more than nine months and two patients maintained stable disease for six and 15 months, respectively [S15]. AR expression was seen in 25% (3/12) of biopsied patients.

Adrenocortical carcinomas: Because chemotherapy is effective in only a minority of patients with adrenocortical carcinomas, steroidogenesis inhibitors such as ketoconazole, mitotane, etomidate and metyrapone, have been used as single agents or combined with cytotoxic chemotherapy [S48]. Barzon et al. [S49] found that 38% (6/16) of patients with adrenocortical carcinoma were AR+ by IHC analysis. Rossi et al. [S50] demonstrated AR RNA in human adrenocortical cancer cell lines. Ketoconazole reduces adrenal steroid biosynthesis by inhibiting cytochrome P450-dependent adrenal enzymes and is effective in reducing hormonal levels in virilizing adrenocortical carcinomas. However, generally no tumor shrinkage has been seen [S51, S52].

Bladder cancer: AR positivity has been found in 13% to 51% of bladder tumors [S53-S55] but not in normal bladder tissue [S55]. Loss of AR correlated with higher grade tumors [S55]; on the other hand, AR positivity was more frequent (71%) in metastatic disease than in primary tumors [S54]. There was no significant difference in the rate of AR positivity between men and women, despite the fact that bladder cancer is more common in men [S53]. Androgen blockage by flutamide in vitro as well as in vivo in mouse xenograft models with human AR-expressing bladder cancer cell lines attenuated proliferation and tumor growth [S56]. Hameed et al. [S57] assessed the combination of ketoconazole and all-trans retinoic acid in 16 patients with superficial bladder cancer, and demonstrated tolerable toxicity and reduced recurrence rate, albeit in the context of a small uncontrolled study.

Prostate cancer: The discussion of prostate cancer herein is limited as AR and prostate cancer has been reviewed extensively elsewhere. Briefly, prostate cancer is a prime example of the potential for therapeutically manipulating hormonal levels (Table 2). This is feasible because strong nuclear AR reactivity is the norm in more than 95% of the samples studied [S58]. There is a high correlation between AR expression and response to hormonal treatment, and anti-androgens are therefore the mainstay of therapy for patients with prostate cancer [S59, S60]. Frequent AR positivity is found in more highly differentiated versus poorly differentiated tumors; further, AR was rarely seen in prostate tumors of patients who had received long-standing hormonal therapy [S61].

V. LUNG MALIGNANCIES

Non-small cell lung cancer: Kaiser et al. [S62] found AR expression in 70.5% (12/17) of non-small cell lung cancer cases. Rades et al. [S63] retrospectively found 31% (20/64) AR positivity in patients who received radiation for stage II/III non-small cell lung cancer.

Small cell lung cancer: Kaiser et al. [S62] mentioned that hormonal receptor expression was almost non-existent in the small cell lung cancer cell lines. Maasberg et al. [S64], however, demonstrated growth stimulation by testosterone and growth inhibition by flutamide in selected AR+ small cell lung cancer cell lines.

VI. GASTROINTESTINAL MALIGNANCIES

Gastric carcinomas: AR positivity has been found in 12.5% (2/16) to 39% (46/117) of gastric cancers [S65-S67]. AR positivity may correlate with poorer survival [S66].

Esophageal carcinomas: Yamashita et al. [S68] found AR positivity in two cases of human esophageal cancer xenografts implanted into nude mice; tumor progression was fueled by testosterone and inhibited by castration. Tihan et al. [S69] documented AR reactivity in 45% (5/11) of adenocarcinomas and 21.4% (3/14) of squamous cell carcinomas of the esophagus, respectively. Esophageal cancer seems to be more frequent in men than in women. However, no difference in the rate of positivity between genders was seen, though the numbers of patients were small, precluding definite conclusions. Interestingly, survival was similar regardless of AR status [S69]. Of possible interest, the Survival Epidemiology and End Results (SEER) registries database showed that patients with prostate cancer are less likely to develop esophageal adenocarcinoma [S70]. The relationship between these facts and treatment with androgen deprivation remains unexplored.

Pancreatic adenocarcinomas: Tumor progression in a nude mice xenograft model was stimulated by testosterone and inhibited by the anti-androgen cyproterone acetate [S71]. However, Targarona et al. [S72] found no AR expression in 12 biopsies of exocrine pancreatic neoplasia. A phase II study of the anti-androgen flutamide in an unselected population of 14 patients with advanced pancreatic adenocarcinoma yielded no objective responses [S73]. Subsequently, a randomized trial showed encouraging prolongation of median survival to 8 months in the flutamide group compared to 4 months in the
placebo group [S74]. A counterpoint, however, is the fact that patients with advanced pancreatic carcinoma have lower than expected testosterone secondary to malnutrition and consumption [S75]. In a preclinical model Konduri et al. [S76] did not show any significant improvement from combining flutamide with gemcitabine or bevacizumab.

Since estrogen receptors may also be expressed in pancreatic cancer, the relationship between androgen and estrogen, when designing clinical trials testing hormonal blockade, will be particularly important in malignancies that express both receptors [S77, S78].

Colorectal adenocarcinomas: Tutton et al. [S79] confirmed that colon tumor cell proliferation was enhanced by testosterone and cell growth was attenuated by flutamide. Stebbing et al. [S80] found cytosolic AR in 39% (9/23) of rectal and 38% (5/13) of cecal adenocarcinomas. Several authors have described AR positivity in almost all samples of both colon tumors and normal mucose [S81, S82], while others have shown smaller, but still significant, percentage of AR positivity (32% colon tumors; 67% non-tumor tissue) [S83]. Further, ketoconazole has antiproliferative effects in human colon cancer cell lines [S84]. In preclinical rat models, cell proliferation in colon tumors was triggered by testosterone and inhibited by flutamide [S79]. However, the fact that normal colorectal mucosa expresses AR might blunt the usefulness of AR inhibitors in colorectal cancer.

VII. CONNECTIVE TISSUE TUMORS

Desmoid tumors: Ishizuka et al. [S85] documented AR expression in 52.9% (14/27) of patients with desmoid tumors. Goserelin, a gonadotropin releasing hormone agonist, resulted in stable disease in two patients with desmoid tumors for 4 and 16 months, respectively [S86]. Bauernhofer et al. [S87] reported a case of inoperable intra-abdominal desmoid tumor that decreased in size after treatment with goserelin acetate and low-dose tamoxifen for 17 months.

VIII. CENTRAL NERVOUS SYSTEM MALIGNANCIES

Glioblastoma multiforme and other intracranial tumors: In preclinical studies, testosterone stimulated proliferation of glioblastoma multiforme cell lines [S88]. Chung et al. [S89] documented AR positivity in 40% (4/10) of glioblastoma multiforme cases, 28% (5/18) of grade I/II astrocytomas and 75% (3/4) of anaplastic astrocytoma. Lee et al. [S90] found AR+ in 42% (8/19) of patients with meningioma.

VIII. GYNECOLOGIC MALIGNANCIES

Cervical cancer: One study demonstrated the expression of AR by immunohistochemistry in 100% (30/30) of normal epithelium, 100% (30/30) of low-grade cervical intraepithelial neoplasia, and 63% (19/30) of high-grade cervical intraepithelial neoplasia, as well as in 23% (3/13) of invasive squamous cell carcinoma. The authors suggested the loss of AR expression is a common occurrence in malignant cervical transformation [S91]. Even so, the fact that significant subsets of gynecologic cancers express AR may have clinical relevance.

Uterine cancer: Yang et al. [S92] found that AR positivity was the most robust variable associated with the risk of endometrial cancer. Ito et al. [S93] found AR reactivity in 88.6% (39/44) of endometrial carcinomas. Brys et al. [S94] found AR expression in 8% (1/12) of normal endometrium compared to 16% (4/25) of endometrial cancers. The reasons for this variability may relate to lack of standardized methodology.

Uterine sarcoma: A review of 65 cases of uterine sarcoma revealed 0% (0/65) AR+ [S95]. In contrast, Moinfar et al. [S96] found AR reactivity in 45% (9/20) of malignant endometrial stromal neoplasms. As benign leiomyomas are responsive to hormonal manipulation; Leitao et al. [S97] showed AR expression in 32% (6/19) of benign uterine leiomyoma and in 40% (10/25) of uterine leiomyosarcoma. AR positivity was predictive of a lower risk of recurrence although, after controlling for stage, AR was not significantly associated with overall survival improvement [S97].

Ovarian cancer: Testosterone binding sites have been found in 43% of normal ovaries, 40% of benign ovarian tumors, and 60.5% of ovarian adenocarcinomas [S98]. Elattar et al. [S99] noted that AR-expressing epithelial cells in ascitic fluid from patients with ovarian cancer were stimulated by dihydrotestosterone and inhibited by bicalutamide. AR expression was significantly reduced in paired samples after chemotherapy which might explain the lack of response to hormonal blockade in heavily pre-treated patients [S99]. Jones et al. [S100] studied steroid cell ovarian tumors, finding AR immunoreactivity in 64% (9/14) of samples. High AR expression in 18% (28/154) of epithelial ovarian cancer was reported [S101]. Patients with AR-positive serous tumors had improved disease-specific survival [S101]. Additionally, reports of transsexuals who developed ovarian cancer in the setting of androgen supplementation suggest a carcinogenic role for AR [S102]. In regard to treatment, a phase II trial of goserelin and bicalutamide in 35 patients with epithelial ovarian cancer did not prolong PFS [S103, S104]. Because chemotherapy reduces AR expression, anti-androgen therapy may be more effective early in the disease [S104]. One study demonstrated dissimilar AR reactivity within a single ovarian neoplasm, attesting to tumor heterogeneity [S105]. In a phase II trial, 32 patients with advanced ovarian neoplasia received a minimum of two months of flutamide resulting in one complete response for 73 weeks, one partial response for 44 weeks, and partial responses in 28% (9/32) for a median of 24 weeks [S106]. A case report documented a patient with Leydig cell ovarian tumor, an androgen-producing neoplasm, which responded to the GnRH-analogue triptoreline [S107]. Because androgen receptors are frequently expressed in epithelial ovarian
cancer, investigation of newer anti-androgens in this disease may be worthwhile [S108].

VIII. BREAST CANCER

Peters et al. studied invasive breast ductal adenocarcinomas, finding 56% AR positivity by IHC, and expression was inversely associated with 10-year survival [S109]. In HER2-positive breast malignancies, AR expression was found in 85.6% (89/104). AR-negative/estrogen receptor-negative was the most aggressive phenotype and correlated with high-grade tumors [S110]. Similarly, Hu et al. [S111] documented AR positivity in 78.7% of 1,467 patients with breast cancer. Pristauz et al. [S112] studied the relationship between AR and BRCA mutations in a population of patients constituted by 32% (43/135) BRCA1 and 13% (18/135) BRCA2. Interestingly, AR reactivity was seen in 30% (13/43) of BRCA1 and in 78% (14/18) in BRCA2, suggesting that many ER-/PR- BRCA-mutant tumors are actually AR positive [S112]. A higher number of breast carcinomas were found to express AR (77%) compared to ER (61%) and PR (60%) in 980 cases, with more than 50% of triple negative tumors expressing AR [S113]. The fact that AR+ was lost by the time of autopsy (5/11) implies loss of AR expression in end-stage metastases [S114]. From a molecular standpoint, Collins et al. [S115] studied 2,171 invasive breast malignancies with tissue microarrays, dividing them into luminal-A (64%), luminal-B (15%), basal-like (11%), and HER2 (6%). AR expression was seen in 77% of invasive breast malignancies divided into

![Figure 1: The road to (androgen) independence.](image)

AR-negative prostate adult stem cells generate AR-negative transit amplifying cells, AR-negative intermediate cells and AR-positive luminal secretory cells. Once therapeutic circulating androgen blockade ensues, AR-positive luminal cells die, giving origin to the adaptive (selected AR-positive luminal cells will continue to thrive despite lack of androgen exposure) and clonal theory of resistance (pre-existent AR-negative cells develop into a malignant clone). Castration-resistant prostate cancer might develop via ligand-dependent (tissue steroidogenesis, AR mutations, AR amplification) and ligand-independent pathways (heightened AR nuclear translocation, AR cross-talk with additional pathways, disturbing the balance between co-activators and co-repressors).
luminal-A (91%), luminal-B (68%), basal-like (32%), and HER2 (59%). Interestingly, AR expression was seen in 86% of 246 cases of ductal carcinoma in situ [S115]. Breast cancer cell lines may be at least AR-dependent [S116, S117]. Other preclinical studies in human breast cancer cell lines showed that AR overexpression induced tamoxifen resistance which was reversed by the AR antagonist bicalutamide [S118]. In regard to treatment, Gucalp et al. [S119] report on a multicenter phase II trial bicalutamide for patients with AR+/ER-/PR- breast cancer showed a clinical benefit rate of 19%.

**DISCUSSION**

Therapeutic implications of AR across malignancies: Lessons from prostate cancer: During the last several decades, androgen deprivation (Table 2, Figure 1) has been standard of care for metastatic prostate cancer; however, most patients eventually develop disease progression despite pharmacologic suppression of testosterone levels [20-22], denoted as castration-resistant prostate cancer (Figure 2) perhaps mediated by androgen independence (Figure 1) [23, 24]. The goals of hormonal deprivation therapy for prostatic cancer are to decrease circulating plasma testosterone to castration levels and to block residual androgen at the cellular level (Figure 3). While orchiectomy is very effective at achieving some of these goals, it does not halt conversion of residual adrenal androgens to dihydrotestosterone (DHT). Certainly, the common examples of potent androgens include testosterone and DHT, which can directly stimulate androgen receptors. Subsequent therapies were added to the hormonal armamentarium including, but not limited to, bicalutamide, a competitive

---

**Figure 2: The fate of testosterone in prostatic tissues.** Testosterone circulates in the blood and is bound to albumin, whereas free testosterone is introduced into prostate cells and is subsequently converted to DHT by 5-alpha-reductase. Binding of DHT to the AR induces dissociation from HSPs and receptor phosphorylation. The AR dimerizes and can bind to androgen-response elements in the promoter regions of target genes, leading to growth, survival and production of PSA. Enzalutamide, formerly called MDV3100, exerts its mechanism of action during several steps in the AR signaling pathway including inhibition of AR binding to androgens, inhibition of nuclear translocation of AR, inhibition of AR association to DNA, and AR amplification. As some of those aberrations may occur late in the disease, it is unknown at this point if enzalutamide will have a role upfront in the management of prostate cancer. Abbreviations: AR, androgen receptor; DHT, dihydrotestosterone; GTA, general transcription activation; HSP, heat-shock protein; SHBG, sex-hormone-binding globulin; AKT, akt serine/threonine kinase; DHEA, dihydroepiandrosterone; ERK, extracellular signal-regulated kinase; P, phosphorylated residues; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
non-steroidal androgen receptor antagonist; flutamide, a non-steroidal anti-androgen; and luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (Gn-RH) [25]. Leydig cells, which are located in the testes, are dependent on LH to produce and secrete testosterone. Gn-RH is a hypothalamic decapeptide that governs the synthesis of pituitary LH; thus synthetic Gn-RH analogues were initially developed to treat infertility in cases of endogenous Gn-RH deficiency. Long-term administration of supra-physiologic Gn-RH produce the paradoxical effect of pituitary overstimulation including pituitary desensitization to Gn-RH, breakdown of physiological feedback systems, down-regulation of Gn-RH receptors, depletion of releasable LH content, and reduction of testosterone secretion to castrate levels. It is not, therefore, surprising that high-dose Gn-RH analogues became a major therapeutic option in prostate cancer, as they bypass the need for orchiectomy [26]. Exogenous estrogens indirectly affect the prostate by disturbing the hypothalamus-pituitary-testes axis as estrogens inhibit the release of Gn-RH from the hypothalamus [27]. Recently, the realization that non-gonadal sources of androgens, such as the adrenal glands and intra-tumoral production, might be critical in the progression of prostate cancer led to the development of abiraterone acetate, an oral specific inhibitor of CYP17A1, which is a rate-limiting enzyme in androgen (and estrogen) synthesis that, when targeted, specifically suppresses adrenal androgens [28]. A novel alternative is the use of intermittent androgen suppression which holds the promise of decreasing toxicity while maintaining efficacy, although the role of intermittent therapy in the metastatic setting remains a challenge [29]. Hussain et al. [30] has studied intermittent versus continuous androgen deprivation in hormone sensitive metastatic prostate cancer patients in a phase III trial and their published final results are eagerly awaited. In the non-metastatic setting, Crook et al. [31] confirmed that intermittent androgen deprivation showed non-inferior overall survival when compared to continuous therapy after prostate irradiation.

Figure 3: Androgen blockade plus mTOR inhibitors: A prime candidate for combination hormonal treatment. The mTORC2/AKT/AR pathway (red arrows) leads to tumor cell proliferation. Rapamycin combined with bicalutamide has an apoptosis-inducing effect in prostate cancer. Rapamycin inhibits both mTOR complexes, mTORC1 with raptor and mTORC2 with rictor; nevertheless abrogation of mTORC2, a kinase for AKT phosphorylation, further inhibits the AR transcription cascade in an AKT-dependent manner. As a counterpoint, abrogation of mTORC1 produces AKT/AR-independent apoptosis, though it continues to stimulate the AR transcriptional cascade and AKT phosphorylation. According to the suggested cross-talk, it would take a combination of androgen blockade plus mTOR inhibitors to fully abrogate the mTORC2/AKT/AR pathway. Barnett et al. [44] found that, out of 47 tumors evaluable by immunohistochemistry, 36% had PTEN loss which was associated with an increased relapse in high risk prostate cancer treated with chemotherapy followed by surgery. PTEN loss activates the AKT/mTOR pathway [45] thus supporting the use of mTOR inhibitors in this condition. Abbreviations: AR, androgen receptor; AKT, aKT serine/threonine kinase.
Finally, there are novel therapeutic agents including the once-daily androgen receptor signaling inhibitor enzalutamide, previously called MDV3100 [32, 33] (Figure 3), which significantly prolonged overall survival in a randomized phase III trial that involved 1,199 men with castration-resistant prostate cancer [34]. Such results triggered the Food and Drug Administration to approve enzalutamide in August of 2012 for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. The recent wave of novel anti-androgen agents, as abiraterone and enzalutamide, serves as proof-of-principle that AR signaling continues even in the so-called castration-resistant prostate cancer population [35].

Tolerance of Anti-Androgens: Hormonal therapy is not devoid of side effects, and depending on the agent used, toxicity can include increased risk of fractures, increased lipoproteins, decreased insulin sensitivity, increased cardiovascular disease, low libido and emasculation [36]; and such toxicity must be kept in mind during the design of future clinical trials.

Overcoming resistance to AR targeted therapy: Relevant molecular pathways: The mTOR (mammalian target of rapamycin) pathway has been hailed as a possible target for suppressing prostate malignancies (Figure 3), as the PI3K/AKT components of the pathway are upregulated in hormone-refractory prostate neoplasia, and because the combination of rapamycin and bicalutamide produces apoptosis in prostate cell lines [37-39]. Indeed, this pathway is deregulated in up to 65% of prostate cancers, most commonly due to PTEN loss, and less commonly related to PIK3CA amplification or mutation [40]. Wang et al. described the regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival [38]. Furthermore, there seems to be cross-talk between AR and the epidermal growth factor receptor (EGFR) (Figure 3), which in turn activates the expression of mTOR [41]. Gonzalez-Angulo et al. [42] found significantly higher AR levels in breast cancer patients with kinase domain PIK3CA mutations versus wild-type PIK3CA. Wang et al. [43] hypothesized that AR halts PTEN transcription in the prostate in contrast to the breast, in which AR promotes PTEN transcription. Barnett et al. [44] found that, out of 47 tumors evaluable by IHC, 36% had PTEN loss which was associated with an increased risk of prostate cancer treated with chemotherapy followed by surgery. PTEN loss activates the PI3K/AKT/mTOR pathway [45] thus supporting the use of mTOR inhibitors in this condition.

While both EGFR and AR directly stimulate cell growth, AR apparently indirectly exerts stimulation of EGFR synthesis by paracrine or autocrine mechanisms [46]. In addition to AR-EGFR crosstalk, Src kinase is implicated in EGFR phosphorylation [47]. Meanwhile, interaction between AR and the MAPK pathway has been demonstrated with HER2-AR-ERK feedback loops in breast cancer [48]. Naderi et al. has documented synergy between flutamide and the HER2 inhibitor AG825; and subsequently, synergy between flutamide and the MEK inhibitor CI-1040 [49, 50]. In a preclinical model, DHT enhanced IL-6 and IL-8 expression and flutamide abrogated IL-6 and IL-8 expression [51]. Darshan et al. suggested that taxanes, microtubule stabilization agents, are active in castrate-resistant prostate cancer and act by inhibiting AR trafficking and the downstream cascade of transcriptional events, including AR target genes such as prostate-specific antigen [52]. Testing this concept, Kuroda et al. [58] treated a patient with metastatic AR-positive salivary duct carcinoma with combined anti-androgen treatment and paclitaxel, achieving a partial response.

Other mechanisms promoting resistance may include genetic and epigenetic adaptation, clonal selection, and evolution of the tumor microenvironment in prostate cancer. The synthesis of constitutively active AR variants lacking the canonical ligand-binding domain may also promote resistance [53].

FUTURE DIRECTIONS

AR is ubiquitously expressed across malignancies. Drawing definitive conclusions about rates of expression is however challenging, mainly due to the lack of standardized AR measurement methods and the relatively small number of patients tested for AR expression. Importantly, there is a paucity of studies of androgen manipulation in AR+ tumors other than prostate cancer. Importantly, some tumors such as salivary gland ductal tumors have AR positivity rates approaching 100%. Anecdotal reports and small studies in a variety of malignancies suggest that AR-positive tumors may respond to hormonal manipulation. Of interest, breast and gynecologic tumors also have high rates of AR positivity (Table 1). The latter may have special clinical relevance [54], especially since aromatase inhibitors, used to suppress estrogen levels in patients with ER+ breast tumors, can raise testosterone levels. As an example, anastrozole increases testosterone levels by decreasing serum estradiol levels [55]. Finally, PIK3CA/ AKT/mTOR signaling is ubiquitously deregulated in cancer, and it is apparent that there is significant crosstalk between this pathway and that related to androgens (Figure 3). Further exploration of androgen modulation in patients with diverse cancers merits investigation.

Conflicts of Interest

The authors have no conflicts of interests to disclose.

REFERENCES

1. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal
management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605.

2. Askew EB, Gampe RT, Jr., Stanley TB, et al. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007;282(35):25801-16.

3. Sadow J, von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol 1988;11 Suppl 1:S6-10.

4. Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006;24(2):71-7.

5. Clark AJ, Metherell LA. Mechanisms of disease: the adrenocorticotropic receptor and disease. Nat Clin Pract Endocrinol Metab 2006;2(5):282-90.

6. Rittmaster RS, Zwicker H, Thompson DL, et al. Androstanediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. J Clin Endocrinol Metab 1993;76(4):977-82.

7. Valle LD, Toffolo V, Nardi A, et al. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J Endocrinol 2006;190(1):129-39.

8. Thomas BC, Neal DE. Androgen deprivation treatment in prostate cancer. BMJ 2013;346:e8555.

9. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005;7 Suppl 5:S3-S12.

10. Lepor H, Shore ND. LHRH Agonists for the Treatment of Prostate Cancer: 2012. Rev Urol 2012;14(1-2):1-12.

11. Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391-402.

12. Gauthier S, Martel C, Labrie F. Steroid derivatives as pure antagonists of the androgen receptor. J Steroid Biochem Mol Biol 2012;132(1-2):93-104.

13. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009;12(4):333-8.

14. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102(4):899-911.

15. Langley RE, Cafferty FH, Alhasso AA, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013;14(4):306-16.

16. Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2013.

17. Salem M, Garcia JA. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr Oncol Rep 2011;13(2):92-6.

18. Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol 2013.

19. Soutoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol 2013;2013:240108.

20. Cannata DH, Kirschbaum A, Levine AC. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 2012;97(2):360-5.

21. Yap TA, Zivi A, Omlin A, et al. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8(10):597-610.

22. Hammes SR, Levin ER. Extraneural steroid receptors: nature and actions. Endocr Rev 2007;28(7):726-41.

23. Tombal B. What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 2011;47 Suppl 3:S179-88.

24. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011;57(10):1366-75.

25. Geller J, Albert JD. Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol 1983;10(4 Suppl 4):34-41.

26. Jacobi GH, Wenderoth UK. Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension. Eur Urol 1982;8(3):129-34.

27. Ricke WA, Wang Y, Cunha GR. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 2007;75(9):871-82.

28. Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs 2010;19(4):563-70.

29. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85.

30. Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 2012;30(18 suppl).

31. Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903.

32. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46.
33. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97.
34. DeBono JS, Fizazi K, Saad F, et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol 2012;30(15_suppl).
35. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29(27):3651-8.
36. Wassersug RJ. Mastering emasculation. J Clin Oncol 2009;27(4):634-6.
37. Kobayashi T, Shimizu Y, Terada N, et al. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate 2010;70(8):866-74.
38. Wang Y, Mikhailova M, Bose S, et al. Regulation of androgen receptor transcriphal activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008;27(56):7106-17.
39. McCall P, Gemmell LK, Mukherjee R, et al. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 2008;98(6):1094-101.
40. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013;31(15):1866-73.
41. Recchia AG, Musti AM, Lanzino M, et al. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol 2009;41(3):603-14.
42. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15(7):2472-8.
43. Wang Y, Romigh T, He X, et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 2011;30(42):4327-38.
44. Barnett CM, Heinrich MC, Lim J, et al. Genetic Profiling to Determine Risk of Relapse Free Survival in High-risk Localized Prostate Cancer. Clin Cancer Res 2013.
45. Zhang W, Haines BB, Efferson C, et al. Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol 2012;5(6):422-9.
46. Mulder E, van Loon D, de Boer W, et al. Mechanism of androgen action: recent observations on the domain structure of androgen receptors and the induction of EGF-receptors by androgens in prostate tumor cells. J Steroid Biochem 1989;32(1B):151-6.
47. Fiorelli A, Ricciardi C, Pannoni G, et al. Interplay between steroid receptors and neoplastic progression in sarcoma tumors. J Cell Physiol 2011;226(11):2997-3003.
48. Chia KM, Liu J, Francis GD, et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 2011;13(2):154-66.
49. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008;10(6):542-8.
50. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13(2):R36.
51. Wang Y, Yang J, Gao Y, et al. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 2007;6(6):864-71.
52. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71(18):6019-29.
53. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm Sm., Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 2014: Aug;21(4):T87-T103.
54. McNamara KM, Moore NL1, Hickey TE1, Sasano H1, Tilley WDComplexities of androgen receptor in breast cancer. Endocr Relat Cancer 2014: Aug;21(4):T161-81. doi: 10.1530/ERC-14-0243. Epub 2014 Jun 2
55. Mechlin CW, Frankel J, McCullough A. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone Pellet insertion. J Sex Med 2013.